Pregnancy is a special and challenging period for women with rheumatism. The issue of how to use medicines in a rational manner, while ensuring the health of mothers and children, is a common concern of the medical community. This requires not only the professional judgement of the doctors, but also the full knowledge of the mothers and their active participation in decision-making.
Rheumatist diseases cover a wide range of diseases, such as rheumatism, systemic red hemorrhoids, etc., which may fluctuate during pregnancy. Some patients may be worried that the drug will harm the fetus, but this may lead to an increase in the condition and, instead, to a greater risk for the mother and the child. In fact, not all drugs are absolutely taboo during pregnancy, and the key is to weigh the trade-offs against the precision of choice.
In the case of non-paralytic anti-inflammatory drugs (NSAIDs), such as Broven, use is relatively safe in the early stages of pregnancy, but use in the late stages of pregnancy may increase the risk of foetal heart malformation and affect the coagulation function at birth, and therefore requires careful use and close monitoring. Sugar cortex hormones often play an important role in activities to control rheumatism. In general, small doses of sugar cortex hormones, such as Pornsson, are available during pregnancy, but long-term high use can lead to complications such as increased blood sugar, blood pressure fluctuations and osteoporosis among pregnant women, and may have some impact on the growth and development of the foetus, such as increased premature birth, low-weight risk, etc.
GHC is special for people with rheumatological conditions during pregnancy in anti-ruin and slow-acting drugs. Research has shown that hydroxychloride is not only effective in controlling systemic red hemorrhoids, reducing the risk of re-emergence, but also contributing to the health of the foetus, reducing the risk of foetal heart-transmission retardation, etc., and can be used throughout without a taboo. As a result of its clearly degenerative effects, the mercuric and fluorinated pharmacoids are suspended for a long period of time prior to gestation, while the mercuric plumes are suspended for three to six months, and the fluorometts are suspended for two years or are monitored at the standard level of the drug after treatment.
In the case of biological agents, there are some safe data on the use of some tumour cause-of-mortem inhibitors during pregnancy, e.g., Ignasip, but careful assessment and close observation of the situation of mothers and children is still required. During their use, doctors develop individualized programmes that take into account a combination of factors such as disease activity, pregnancy week and drug safety.
Drug management of patients with rheumatizing diseases during pregnancy is a dynamic process. During pregnancy, disease activity indicators, maternal health and foetal development are closely monitored. Regular birth tests, ultrasound examinations and monitoring of relevant blood indicators are essential. At the same time, patients are required to maintain good living habits, such as a balanced diet, moderate rest and exercise, and the avoidance of infection, in order to maintain a stable condition in coordination with medication.
In the event of rheumatism, mothers must not choose to use or stop their medication, and must communicate fully with rheumatologists and gynaecologists. It is only through multidisciplinary collaboration, based on a scientific basis and a combination of individual circumstances, that a drug can be used rationally during pregnancy, both to control rheumatism and to ensure the safety and health of the mother and the child and to meet the prospect of a new life.
